Related posts

cash, credit and health3 Promising Healthcare Stocks3 Best Cyclical and Value ETFs
Investor Insights

This summary was created by AI, based on 6 opinions in the last 12 months.

Experts have mixed opinions on Health Care Select Sector SPDR Fund (XLV-N). Some believe it offers defensive protection with strength in the healthcare sector, creating a buying opportunity. Others suggest avoiding the stock as it's making new lows compared to the market. The fund holds a basket of names, with some winners like LLY, JNJ, and PFE and others like NVO, MCK, and CAH. Overall, healthcare is considered a leader in the market and a broad-based US healthcare strategy. Energy, tech, and healthcare are expected to lead sales growth in the second half of 2024. Second-half 2024 earnings comps are viewed as compelling, indicating potential for growth.

Consensus
Mixed
Valuation
Fair Value
PAST TOP PICK
(A Top Pick May 03/24, Up 4%)

(Note the short timeframe.)  A defensive pick at the time. Sector did well until September, then started to break down. He sold. When the market's running hot, healthcare doesn't take off. Not now in a seasonally strong period.

E.T.F.'s
WAIT

Making RSI new lows versus the market. Avoid this whole neighbourhood for a while.

E.T.F.'s
DON'T BUY
XLV vs. individual names.

A basket of names, with some winners and some losers. LLY is the top holding, that's a winner. Also holds JNJ and PFE, which haven't done particularly well. 

He owns NVO, MCK and CAH. He likes those companies where the only serious competition comes from 1 or 2 others, as they can control pricing power. Diabetes and weight loss are definite growth areas. See his Top Picks.

E.T.F.'s
BUY

Energy, tech and healthcare will likely lead sales growth in the second half of 2024.

E.T.F.'s
BUY

Second-half 2024 comps in earnings are compelling.

E.T.F.'s
TOP PICK

Excellent name that offers defensive protection. Strength in health care sector good for investors. Weakness in sector that past 1-2 years is creating buying opportunity. 

E.T.F.'s
BUY

Likes healthcare in general, a larger weight for him. Healthcare has been the leader YTD, only 11 days into the new year. The XLV would make sense for a broad-based, US healthcare strategy. IXJ is the global version of that.

E.T.F.'s
PAST TOP PICK
(A Top Pick May 05/23, Down 7%)

Bought this to be defensive, however, health care wasn't that defensive this year. Now, HC is past seasonality and he doesn't like it.

E.T.F.'s
BUY

The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters. 

E.T.F.'s
COMMENT

Parts of healthcare are doing very well: equipment, disposables, more surgical procedures, managed care. Does this translate into stronger earnings and growth even during an economic contraction?

E.T.F.'s
BUY

She picked it to start the year, but it hasn't performed well in the first six months. Healthcare has lagged this year, but when the VIX is this low, you want to hold defence.

E.T.F.'s
BUY

She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.

E.T.F.'s
BUY

She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.

E.T.F.'s
TOP PICK

Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.

E.T.F.'s
BUY
She's not a fan of ETFs, this single-brushstroke style of investing, but an ETF makes sense in health care, because the companies are very different. Some will excel while others will flame out (considering their drug pipelines).
E.T.F.'s
Showing 1 to 15 of 60 entries

Health Care Select Sector SPDR Fund(XLV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 5

Stockchase rating for Health Care Select Sector SPDR Fund is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Health Care Select Sector SPDR Fund(XLV-N) Frequently Asked Questions

What is Health Care Select Sector SPDR Fund stock symbol?

Health Care Select Sector SPDR Fund is a American stock, trading under the symbol XLV-N on the NYSE Arca (XLV). It is usually referred to as AMEX:XLV or XLV-N

Is Health Care Select Sector SPDR Fund a buy or a sell?

In the last year, 5 stock analysts published opinions about XLV-N. 4 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Health Care Select Sector SPDR Fund.

Is Health Care Select Sector SPDR Fund a good investment or a top pick?

Health Care Select Sector SPDR Fund was recommended as a Top Pick by on . Read the latest stock experts ratings for Health Care Select Sector SPDR Fund.

Why is Health Care Select Sector SPDR Fund stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Health Care Select Sector SPDR Fund worth watching?

5 stock analysts on Stockchase covered Health Care Select Sector SPDR Fund In the last year. It is a trending stock that is worth watching.

What is Health Care Select Sector SPDR Fund stock price?

On 2024-12-06, Health Care Select Sector SPDR Fund (XLV-N) stock closed at a price of $144.255.